Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
LifeMD, Inc. Market Cap
Based on ratings from 0 stock analysts, the LifeMD, Inc. stock price is expected to increase by 168.59% in 12 months. This is calculated by using the average 12-month stock price forecast for LifeMD, Inc.. The lowest target is $10 and the highest is $16. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedLFMD 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect LifeMD, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on LFMD. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of LFMD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sarah James Cantor Fitzgerald | Overweight | $15 | Reiterates | Sep 20, 2024 |
| Sarah James Cantor Fitzgerald | Overweight | $15 | Reiterates | Aug 20, 2024 |
| Sarah James Cantor Fitzgerald | Overweight | $15 | Reiterates | Aug 9, 2024 |
| Scott Schoenhaus Keybanc | Overweight | $10 | Maintains | Jul 11, 2024 |
| Scott Schoenhaus Keybanc | Overweight | $12 | Initiates | Jun 5, 2024 |
| William Woods B. Riley Securities | Buy | $12 | Reiterates | May 21, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | May 10, 2024 |
| Sarah James Cantor Fitzgerald | Overweight | $15 | Maintains | May 9, 2024 |
| David Larsen BTIG | Buy | $14 | Maintains | Apr 23, 2024 |
| David Larsen BTIG | Buy | $13 | Maintains | Mar 15, 2024 |
| Alex Fuhrman Craig-Hallum | Buy | $15 | Maintains | Mar 12, 2024 |
| William Woods B. Riley Securities | Buy | $12 | Reiterates | Mar 12, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Mar 12, 2024 |
| Sarah James Cantor Fitzgerald | Overweight | $11 | Maintains | Mar 12, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Maintains | Jan 11, 2024 |
| Sarah James Cantor Fitzgerald | Overweight | $9 | Reiterates | Dec 14, 2023 |
| Alex Fuhrman Craig-Hallum | Buy | $10 | Initiates | Nov 30, 2023 |
| Sarah James Cantor Fitzgerald | Overweight | $9 | Maintains | Nov 14, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $10 | Maintains | Nov 9, 2023 |
| Sarah James Cantor Fitzgerald | Overweight | $8 | Maintains | Oct 2, 2023 |
When did it IPO
2021
Staff Count
207
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Justin Schreiber
Market Cap
$201.6M
In 2023, LFMD generated $152.5M in revenue, which was a increase of 28.15% from the previous year. This can be seen as a signal that LFMD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - LifeMD, Inc. (Nasdaq: LFMD) has declared a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP).
Why It Matters - LifeMD's declaration of a cash dividend signals strong financial health and commitment to returning value to preferred shareholders, potentially boosting investor confidence and stock demand.
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - LifeMD's Q2 2024 earnings were mixed, with no value assigned to the WorkSimpli asset. The price target is revised from $20 to $15 per share by summer 2025 due to management credibility and GLP1 uncertainties.
Why It Matters - Mixed earnings and unmonetized assets raise concerns about management's credibility, impacting stock valuation and future growth prospects, particularly in the competitive telehealth sector.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - LifeMD, Inc. (Nasdaq: LFMD) will participate in several investor conferences in September 2024, highlighting its position in virtual primary care services.
Why It Matters - LifeMD's participation in investor conferences signals potential growth and increased visibility, which could positively influence stock performance and investor sentiment.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - LifeMD, Inc. (NASDAQ: LFMD) will host its Q2 2024 earnings conference call on August 7, 2024, at 4:30 PM ET, featuring key executives and analysts from several firms.
Why It Matters - LifeMD's Q2 2024 earnings call provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Wed, 07 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - LifeMD, Inc. (LFMD) reported a quarterly loss of $0.19 per share, worse than the expected loss of $0.13, but an improvement from a loss of $0.23 per share a year prior.
Why It Matters - LifeMD's larger-than-expected loss signals potential operational issues, impacting investor confidence and possibly leading to stock price volatility. Year-over-year improvement might provide some reassurance.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - LifeMD, Inc. reported Q2 2024 revenue of $50.7M, up 41% YoY, with telehealth revenue rising 67%. Adjusted EBITDA reached $2.5M, and cash totaled $35.7M. Subscribers exceeded 60,000.
Why It Matters - The strong revenue growth, profitability of telehealth, and increasing subscriber base signal robust demand and operational efficiency, enhancing LifeMD's investment appeal.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
